15 Multiple Myeloma Clinical Trials in Nashville, TX (2026)

Q: How do I join a clinical trial in Nashville?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Nashville research site will contact you.

Recruiting Multiple Myeloma Studies in Nashville

NCT07403721Recruiting

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

The primary objectives of this trial are to evaluate the safety profile of AMG 436 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for AMG 436 as monotherapy and in combi...

Nashville, TX464 participantsAmgen

View Study Details

NCT07246590Recruiting

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)

This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-301; referred to as COVE-2 \[Cantharidin and Occlusion in Verruca Epithelium\]) to evaluate the efficacy and s...

Nashville, TX300 participantsVerrica Pharmaceuticals Inc.

View Study Details

NCT05231629Recruiting

Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

This research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is mu...

Nashville, TX300 participantsUniversity of Alabama at Birmingham

View Study Details

NCT05215327Recruiting

High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients

Lung allograft recipients have a higher burden of influenza disease and greater associated morbidity and mortality compared with healthy controls. Induction and early maintenance immunosuppression is ...

Nashville, TX270 participantsVanderbilt University Medical Center

View Study Details

NCT05862012Recruiting

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

This study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of ISB 2001 in participants with relapsed/refractory multiple myeloma (R/R MM)....

Nashville, TX200 participantsIchnos Sciences SA

View Study Details

NCT06750731Recruiting

Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention

The goal of this observational study is to assess the feasibility and effectiveness of a remote monitoring digital health system on adherence, clinical outcomes, and healthcare utilization in patients...

Nashville, TX200 participantsMercy Medical Center

View Study Details

NCT06153251Recruiting

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM)....

Nashville, TX187 participantsJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

View Study Details

NCT07116616Recruiting

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the safety and tolerability of mRNA-2808 in participants with relapsed or refractory multiple myeloma (RRMM)....

Nashville, TX166 participantsModernaTX, Inc.

View Study Details

NCT06055439Recruiting

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

The goal of this clinical trial is to evaluate CHM-2101, an autologous CDH17 CAR T-cell therapy for the treatment of advanced gastrointestinal (GI) cancers that are relapsed or refractory to at least ...

Nashville, TX135 participantsChimeric Therapeutics

View Study Details

NCT05714839Recruiting

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

The study consists of three parts: Part 1 The primary purpose of this part aims to evaluate the safety, tolerability, and clinical activity of escalating doses of single agent Unconjugated belantamab ...

Nashville, TX123 participantsGlaxoSmithKline

View Study Details

NCT06974786Recruiting

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

This is an open-label, multi-site, Phase II randomized trial with response-adaptive design for newly diagnosed multiple myeloma (NDMM) participants who have had prior induction therapy. The primary ob...

Nashville, TX100 participantsSCRI Development Innovations, LLC

View Study Details

NCT05972135Recruiting

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients...

Nashville, TX100 participantsSCRI Development Innovations, LLC

View Study Details

NCT07192458Recruiting

High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)

This will be a follow-up study to the "Comparison of High Dose vs. Standard Dose Influenza Vaccine in Lung Allograft Recipient" study (DMID Protocol Number 22-0014) at Vanderbilt University Medical Ce...

Nashville, TX60 participantsVanderbilt University Medical Center

View Study Details

NCT07073547Recruiting

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM)....

Nashville, TX40 participantsAstraZeneca

View Study Details

NCT06964269Recruiting

Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease

Single-site, open label pilot study of 20 autoimmune patients diagnosed with dry eye demonstrating via the proparacaine challenge some peripheral corneal pain component. At least 16 patients will rece...

Nashville, TX20 participantsToyos Clinic

View Study Details

About Multiple Myeloma Clinical Trials in Nashville

Multiple myeloma is a cancer of plasma cells in the bone marrow that produce abnormal antibodies. It can cause bone damage, kidney problems, and immune deficiency. Treatments have advanced significantly with proteasome inhibitors, immunomodulatory drugs, and CAR-T cell therapy.

There are currently 15 multiple myeloma clinical trials recruiting participants in Nashville, TX. These studies are seeking a combined 2,665 participants. Research is being sponsored by Amgen, Verrica Pharmaceuticals Inc., University of Alabama at Birmingham and 10 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Multiple Myeloma Clinical Trials in Nashville — FAQ

Are there multiple myeloma clinical trials in Nashville?

Yes, there are 15 multiple myeloma clinical trials currently recruiting in Nashville, TX. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Nashville?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Nashville research site will contact you about next steps.

Are clinical trials in Nashville free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Nashville studies also compensate for your time and travel.

What multiple myeloma treatments are being tested?

The 15 active trials in Nashville are testing new therapies including novel drugs, biologics, and treatment approaches for multiple myeloma.

Data updated July 13, 2026 from ClinicalTrials.gov